{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:22Z","timestamp":1793036362831,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007309","name":"Japanese Society of Medical Oncology","doi-asserted-by":"publisher","award":["Japanese Society of Medical Oncology"],"award-info":[{"award-number":["Japanese Society of Medical Oncology"]}],"id":[{"id":"10.13039\/501100007309","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Society of Clinical Oncology","award":["Japanese Society of Clinical Oncology"],"award-info":[{"award-number":["Japanese Society of Clinical Oncology"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03203-y","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:23Z","timestamp":1790344943000},"page":"2537-2545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (2nd edition)\u2014gastrointestinal cancers"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5533-7096","authenticated-orcid":false,"given":"Naoya","family":"Ishibashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the JSMO\/JSCO Clinical Practice Guideline Committee for Pharmacotherapy in Older Adults with Cancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"3203_CR1","doi-asserted-by":"crossref","unstructured":"Tanaka H, Arai K, Katanoda K. Updated Trends in Cancer Statistics in Japan: Incidence in 1985\u20132021 in selected prefectures and Mortality in 1979\u20132023-Beyond the Launch of the National Cancer Registry in 2016.\u00a0J Epidemiol. Published online March 21, 2026.","DOI":"10.2188\/jea.JE20250559"},{"key":"3203_CR2","unstructured":"Cancer Information Services, National Cancer Center, Japan. Current Cancer Statistics, Download Portal of Tables (Japanese). Accessed 14 May 2026. Available from:\u00a0https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html"},{"issue":"3","key":"3203_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.bjc.6604201","volume":"98","author":"A Hurria","year":"2008","unstructured":"Hurria A, Lichtman SM (2008) Clinical pharmacology of cancer therapies in older adults. Br J Cancer 98(3):517\u2013522","journal-title":"Br J Cancer"},{"issue":"26","key":"3203_CR4","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR et al (2023) Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol 41(26):4293\u20134312","journal-title":"J Clin Oncol"},{"key":"3203_CR5","unstructured":"Japanese Society of Medical Oncology (JSMO), Japan Society of Clinical Oncology (JSCO), eds. Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer (second edition). Nankodo; 2026. Japanese."},{"issue":"8","key":"3203_CR6","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/s10147-026-03100-4","volume":"31","author":"A Matsuoka","year":"2026","unstructured":"Matsuoka A, Nagashima F, Ogawa A et al (2026) Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview. Int J Clin Oncol 31(8):1422\u20131430","journal-title":"Int J Clin Oncol"},{"key":"3203_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10120-015-0549-1","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H, Yamada Y, Tanabe S et al (2016) Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer 19:919\u2013926","journal-title":"Gastric Cancer"},{"key":"3203_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jgo.2017.01.002","volume":"8","author":"IG Hwang","year":"2017","unstructured":"Hwang IG, Ji JH, Kang JH et al (2017) A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 8:170\u2013175","journal-title":"J Geriatr Oncol"},{"key":"3203_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199553","volume":"13","author":"J Peng","year":"2018","unstructured":"Peng J, Tan C, Zeng X et al (2018) Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. PLoS ONE 13:e0199553","journal-title":"PLoS ONE"},{"key":"3203_CR10","first-page":"238","volume":"3","author":"DF Bo","year":"2015","unstructured":"Bo DF, Hu XF (2015) Clinical study of S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for elderly patients with advanced gastric cancer. J Int Transl Med 3:238\u2013242","journal-title":"J Int Transl Med"},{"key":"3203_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4143\/crt.2023.333","volume":"55","author":"KW Lee","year":"2023","unstructured":"Lee KW, Zang DY, Ryu MH et al (2023) A phase 3 randomized clinical trial to compare efficacy and safety between combination therapy and monotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10). Cancer Res Treat 55:1250\u20131260","journal-title":"Cancer Res Treat"},{"key":"3203_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","volume":"7","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA et al (2021) Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol 7:869\u2013877","journal-title":"JAMA Oncol"},{"key":"3203_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"3203_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10120-011-0118-1","volume":"15","author":"A Sawaki","year":"2012","unstructured":"Sawaki A, Ohashi Y, Omuro Y et al (2012) Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 15:313\u2013322","journal-title":"Gastric Cancer"},{"key":"3203_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00280-015-2881-x","volume":"76","author":"YS Kim","year":"2015","unstructured":"Kim YS, Sym SJ, Baek MY et al (2015) Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Cancer Chemother Pharmacol 76:1267\u20131272","journal-title":"Cancer Chemother Pharmacol"},{"key":"3203_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10120-017-0766-x","volume":"21","author":"Y Kimura","year":"2018","unstructured":"Kimura Y, Fujii M, Masuishi T et al (2018) Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer 21:421\u2013427","journal-title":"Gastric Cancer"},{"key":"3203_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6:1571\u20131580","journal-title":"JAMA Oncol"},{"key":"3203_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340","journal-title":"Lancet"},{"key":"3203_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M et al (2022) Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603:942\u2013948","journal-title":"Nature"},{"key":"3203_CR20","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M et al (2024) First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 42:2012\u20132020","journal-title":"J Clin Oncol"},{"key":"3203_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013247","journal-title":"Lancet Oncol"},{"key":"3203_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku N, Omori T, Shitara K et al (2024) Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer 27:1287\u20131301","journal-title":"Gastric Cancer"},{"issue":"10389","key":"3203_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389):1655\u20131668","journal-title":"Lancet"},{"key":"3203_CR24","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141","journal-title":"Nat Med"},{"key":"3203_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24:1181\u20131195","journal-title":"Lancet Oncol"},{"key":"3203_CR26","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.2013.49.6638","volume":"31","author":"NJ McCleary","year":"2013","unstructured":"McCleary NJ et al (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II\/III colon cancer: findings from the ACCENT database. J Clin Oncol 31:2600\u20132606","journal-title":"J Clin Oncol"},{"key":"3203_CR27","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","volume":"33","author":"HJ Schmoll","year":"2015","unstructured":"Schmoll HJ et al (2015) Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 33:3733\u20133740","journal-title":"J Clin Oncol"},{"key":"3203_CR28","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","volume":"30","author":"C Tournigand","year":"2012","unstructured":"Tournigand C et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 30:3353\u20133360","journal-title":"J Clin Oncol"},{"key":"3203_CR29","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768\u20133774","journal-title":"J Clin Oncol"},{"key":"3203_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdv003","volume":"26","author":"DG Haller","year":"2015","unstructured":"Haller DG et al (2015) Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized controlled trials. Ann Oncol 26:715\u2013724","journal-title":"Ann Oncol"},{"key":"3203_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/oncolo\/oyac082","volume":"27","author":"L Khalil","year":"2022","unstructured":"Khalil L et al (2022) Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer. Oncologist 27:740\u2013750","journal-title":"Oncologist"},{"key":"3203_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejca.2018.03.022","volume":"96","author":"O Margalit","year":"2018","unstructured":"Margalit O et al (2018) A new look at the International duration evaluation of adjuvant therapy (IDEA) classification-defining novel predictive and prognostic markers in stage III colon cancer. Eur J Cancer 96:105\u2013110","journal-title":"Eur J Cancer"},{"key":"3203_CR33","first-page":"e549","volume":"17","author":"D Brungs","year":"2018","unstructured":"Brungs D et al (2018) Safety and efficacy of oxaliplatin doublet adjuvant chemotherapy in elderly patients with stage III colon cancer. Clin Colorectal Cancer 17:e549\u2013e555","journal-title":"Clin Colorectal Cancer"},{"key":"3203_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.01.051","volume":"148","author":"G Rosati","year":"2021","unstructured":"Rosati G et al (2021) Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: a subgroup analysis from the TOSCA trial. Eur J Cancer 148:190\u2013201","journal-title":"Eur J Cancer"},{"key":"3203_CR35","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.23.01326","volume":"42","author":"C Gallois","year":"2024","unstructured":"Gallois C et al (2024) Oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: an ACCENT\/IDEA pooled analysis of 12 trials. J Clin Oncol 42:2295\u20132305","journal-title":"J Clin Oncol"},{"key":"3203_CR36","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.23.02722","volume":"42","author":"A Takashima","year":"2024","unstructured":"Takashima A et al (2024) Oxaliplatin added to fluoropyrimidine\/bevacizumab as initial therapy for unresectable metastatic colorectal cancer in older patients: a multicenter, randomized, open-label phase III trial (JCOG1018). J Clin Oncol 42:3967\u20133976","journal-title":"J Clin Oncol"},{"key":"3203_CR37","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1200\/JCO.23.00506","volume":"41","author":"S Lonardi","year":"2023","unstructured":"Lonardi S et al (2023) Initial panitumumab plus fluorouracil, leucovorin, and oxaliplatin or plus fluorouracil and leucovorin in elderly patients with RAS and BRAF wild-type metastatic colorectal cancer: the PANDA trial by the GONO foundation. J Clin Oncol 41:5263\u20135273","journal-title":"J Clin Oncol"},{"key":"3203_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S2468-1253(19)30041-X","volume":"4","author":"SB Winther","year":"2019","unstructured":"Winther SB et al (2019) Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomized, open-label phase 2 trial. Lancet Gastroenterol Hepatol 4:376\u2013388","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3203_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/annonc\/mdv491","volume":"27","author":"T Aparicio","year":"2016","unstructured":"Aparicio T et al (2016) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001\u201302). Ann Oncol 27:121\u2013127","journal-title":"Ann Oncol"},{"key":"3203_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/COC.0b013e31825d52d5","volume":"36","author":"YS Hong","year":"2013","unstructured":"Hong YS et al (2013) Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean cancer study group CO06-01. Am J Clin Oncol 36:565\u2013571","journal-title":"Am J Clin Oncol"},{"key":"3203_CR41","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour MT et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet 377:1749\u20131759","journal-title":"Lancet"},{"key":"3203_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00384-018-3053-3","volume":"33","author":"T Landre","year":"2018","unstructured":"Landre T et al (2018) Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidine in the first-line treatment of metastatic colorectal cancer in elderly patients. Int J Colorectal Dis 33:1125\u20131130","journal-title":"Int J Colorectal Dis"},{"key":"3203_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2016.09.029","volume":"74","author":"T Aparicio","year":"2017","unstructured":"Aparicio T et al (2017) Geriatric factors analyses from FFCD 2001\u201302 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer 74:98\u2013108","journal-title":"Eur J Cancer"},{"key":"3203_CR44","doi-asserted-by":"publisher","first-page":"S1390","DOI":"10.1016\/j.annonc.2023.09.139","volume":"34","author":"A Makiyama","year":"2023","unstructured":"Makiyama A, Shoji H, Kawakami H et al (2023) A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G. Ann Oncol 34:S1390","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03203-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:03:50Z","timestamp":1793034230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03203-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03203-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tetsuya Hamaguchi has received honoraria from Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Bristol Myers Squibb, Bayer, Daiichi Sankyo, and Astellas Pharma. He has also received research funding from Chugai Pharmaceutical, Ono Pharmaceutical, BeiGene, Astellas Pharma, AstraZeneca, Pfizer, Bristol Myers Squibb, and Incyte Japan. Fumio Nagashima has received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Janssen, Merck Biopharma, and Daiichi Sankyo. He has also received research funding from Ono Pharmaceutical, OncoTherapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Sumitomo Dainippon Pharma, Daiichi Sankyo, Shionogi, J-Pharma, Bristol Myers Squibb, Kyowa Kirin, Mochida Pharmaceutical, Astellas Pharma, Bayer, MSD, Eisai, NanoCarrier, Janssen, Baxalta\/Shire, and Novartis. Ayumu Matsuoka has received honoraria from Chugai Pharmaceutical and Taiho Pharmaceutical. Akitaka Makiyama has received honoraria from Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, and Daiichi Sankyo Co., Ltd. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}